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Kathryn B. Garber1,*An Aspirin a Day Keeps the Colorectal Cancer Away
Families with Lynch syndrome are predisposed to develop
several different cancers, the greatest risk being for colo-
rectal cancer. Other than intensive screening protocols,
we have no preventive measures to offer at-risk individuals
in these families. This is now changing with the latest
report from the Colorectal Adenoma/Carcinoma Preven-
tion Programme 2 (CAPP2) study, which argues that daily
aspirin therapy should be standard of care for individuals
with Lynch syndrome. In follow-up results of this random-
ized, double-blind trial, daily aspirin reduced the incidence
of colorectal cancer in Lynch syndrome carriers. This effect
became apparent approximately 3 years after the treat-
ment was initiated, and it was significant in the group of
individuals who were on treatment for two or more years.
Although the optimal dose and duration of aspirin therapy
in this group has not been established, this is a goal of the
CAPP3 study.
Burn et al. Lancet 378: 2081–2087.Tipping a Delicate Balance
Although the obvious signs of a primary immunodefi-
ciency would be recurrent or unusual infections that are
resistant to treatment, some individuals actually present
with gastrointestinal disease, often including diarrhea
and nutrient malabsorption. Perhaps the simplest assump-
tion is that this is caused by chronic infections in the gut,
but a recent paper by Shulzhenko et al. suggests the link
between immune deficiency and malabsorption is more
complicated. In mice, the researchers found that in the
absence of B cells, there is a shift in gene expression in
favor of genes involved in the immune response that
occurs at the expense of genes that regulate metabolism.
Similar patterns occur in people with common variable
immunodeficiency. Without a normal adaptive immune
response, the intestinal epithelium itself responds to
commensal bacteria by shifting the balance of gene expres-
sion away from metabolic functions toward an interferon-
inducible immune response. Because of this down-regula-
tion of genes involved in metabolism, B cell deficient
mice absorb fat less efficiently and have lower leptin levels.
Beyond individuals with primary immunodeficiencies,
this homeostatic mechanism involving the intestinal
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with HIV, who also commonly suffer from fat malabsorp-
tion and wasting.
Shulzhenko et al. Nature Medicine 17: 1585–1593.Red Flags
Early-onset cancers, multiple cancers, unusual cancers:
these are all red flags that we use to assess the likelihood
that there is an inherited cancer predisposition in a family.
In the context of expensive, gene-by-gene testing, we use
these red flags to target the families most likely to have
such a mutation. With newer technologies, the reduced
cost and increased ability to look at many genes at once
reduce barriers to testing but begs the question of when
and how this testing should be used. A recent paper by
Walsh et al. suggests that we may need to do away with
the ‘‘red flag’’ approach and instead look broadly for muta-
tions in women with certain cancers. The research group
used a targeted capture and massively parallel-sequencing
approach to look for germline mutations in 21 tumor
suppressor genes in 360 consecutively sampled women
with ovarian, peritoneal, or fallopian tube carcinoma.
Among the group, 24% had germline loss-of-function
mutations, and many of these women had no indication
that an inherited cancer mutation was present in them-
selves or their families. For instance, very nearly one-third
of these women lacked a family history of breast or ovarian
cancer, and one-third wereR60 years of age at the cancer
diagnosis. On the basis of these data, the authors make the
bold statement that genetic testing is warranted for all
women with ovarian, peritoneal, or fallopian tube cancer,
regardless of the presence or absence of red flags.
Walsh et al. PNAS 108: 18032–18037.Nationwide LSD Newborn Screening Study in Austria
The technical ability to screen for lysosomal storage disor-
ders (LSD) via dried bloodspots, coupled with the develop-
ment of interventions for some of these disorders, has led
a handful of states to legislate newborn screening for
particular LSDs. However, it is difficult to anticipate all of
the practical issues associated with the implementation
of this screening on a population basis. A recent, nation-
wide study in Austria tackled this issue, and the results
highlight some of the tricky issues associated with LSDta, GA 30322, USA
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screening. Blood samples from more than 34,000 babies
were collected as part of routine screening in this central-
ized, national program but were then anonymized and
screened for Gaucher, Pompe, Fabry, and Niemann-Pick
diseases. From a technical standpoint, the screens were
successful in that the positive predictive values for these
screens were similar to those for other newborn screens,
and the overall incidence of this group of disorders was
even higher than expected, with 1 in 2,315 babies
confirmed to have mutations in the relevant gene.
However, there were issues that beg mention. Of the muta-
tions identified, 75% were predicted to be associated with
late-onset and slow disease progression, a disease class
that some argue should not be included in newborn
screens. In addition, there were 22 babies with confirmed
low enzyme activity who were classified as negative for
disease because variants of unknown significance, rather
than known mutations, were discovered in the relevant
genes. Finally, three of the nine babies whowere diagnosed
with Fabry disease were girls, a group in which it can be
difficult to predict outcome for this X-linked condition.
These data highlight the capacity, and also the challenges,
of large-scale newborn screening for LSDs.
Mechtler et al. Lancet. Published online 11/30/11, doi:
10.1016/S0140-6736(11)61266-X.
Clopidogrel Pharmacogenetics
A standard of care for individuals having angioplasty or
for those who have had a heart attack is to prescribe
a combination of clopidogrel and aspirin to prevent subse-
quent cardiovascular events by reducing clotting. This
makes clopidogrel, or Plavix, one of the most widely used4 The American Journal of Human Genetics 90, 3–4, January 13, 2012medicines for cardiovascular disease. Clopidogrel is a pro-
drug that must be activated in order to work. This conver-
sion occurs less efficiently in some people than in others,
meaning that these individuals ultimately have less
platelet inhibition and are therefore at a higher risk of
a cardiovascular event. This response variability is largely
due to a common loss-of-function allele in CYP2C19,
which encodes a cytochrome P450 enzyme that metabo-
lizes clopidogrel. In response to this pharmacogenetic
information, the Food and Drug Administration in 2010
put a boxed warning on clopidogrel to warn healthcare
professionals that some people may not respond as well
to the drug. However, clear data have been lacking as to
how to manage these nonresponders. Mega et al. recently
completed a prospective trial to determine whether higher
doses of clopidogrel could improve the drug response in
people with the loss of function CYP2C19*2 allele. In
fact they do; similar levels of platelet inhibition were
achieved in heterozygous CYP2C19*2 carriers compared
to noncarriers by tripling the clopidogrel dose to 225 mg
daily. On the other hand, even a 300 mg daily dose was
not able to reduce platelet inhibition to the same level in
the group homozygous for CYP2C19*2. This work
supports the utility of genotyping CYP2C19 in individuals
being prescribed clopidogrel in order to identify CYP2C19*
2 homozygotes who should be prescribed an alternative
medication. In CYP2C19*2 carriers, on the other hand,
prescribing an increased clopidogrel dose looks like it
may reduce the variability in response to clopidogrel, but
longer-term follow-up studies are needed to ensure that
these higher doses are well tolerated.
Mega et al. JAMA 306: 2221–2228.This Month in Our Sister JournalsThe Ups and Downs of Effective Population Size
A key parameter in population genetics that can help us to
understand the level of genetic diversity in the population
is the effective population size, Ne. In contrast to the actual
number of individuals in a population, this estimate
reflects the number that contribute to the next generation.
Public health researchers sometimes use population
genetics theory to understand viral epidemics. However,
the way in which Ne is typically calculated means that it
is most sensitive to the smallest population sizes over
time, making the estimated Ne a poor reflection of the
true history of viral populations, which tend to havedrastic fluctuations in population size and birth rates
over time. Volz et al recently came up with a more
complex, coalescent model to study these populations.
One can incorporate into the model known information
about the epidemic as well as genetic information from
the viral population in order to produce unbiased esti-
mates of the population size. This type of model should
foster the integration of population genetics into popula-
tion dynamics models in order to better understand
epidemics.
Volz. Genetics. Published online 10/31/11, doi: 10.1534/
genetics.111.134627.
